Ofev (nintedanib) is a small molecule that inhibits multiple receptor tyrosine kinases that play an important role in the pathogenesis of fibrosis. The inhibition of these receptors is believed to decrease collagen and fibronectin formation, thereby slowing the rate of decline in pulmonary function in patients with systemic sclerosis.

If you have a Hayes login, click here to view the full report on the Knowledge Center.